Apr 6, 2021 — 4 min read
Lunit’s AI-powered biomarker platform ‘Lunit SCOPE’ shows association between spatial distribution of immune cells and genomic profile
Lunit to present in AACR for three consecutive years from 2019: “Our AI can bring a new paradigm in the field of cancer treatment”
Lunit will present three abstracts featuring its AI research on cancer treatment at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021. Due to the current COVID-19 pandemic, the meeting will be held online from April 10-15 and May 17-21.
Lunit has been showcasing its findings at AACR since 2019. The studies mainly focus on developing a new AI biomarker that can be applied in cancer treatment. With its proprietary deep learning algorithm, the company is developing an AI-powered biomarker platform called ‘Lunit SCOPE IO’. The platform analyzes cancer patients’ tissue slide images and predicts response to immunotherapy.
Lunit SCOPE IO analyzes a patient's cancer tissue slide image by observing the distribution of tumor-infiltrating lymphocytes (TIL), one of the representative immune cells, and accurately classifies the result into three immune phenotypes (3-IP; inflamed, excluded, desert). So far, Lunit’s research shows that when such AI-based classification is used with the current biomarker, PD-L1, it is possible to predict the treatment response of immunotherapy with enhanced accuracy, demonstrating the effectiveness of the new AI biomarker.
During the poster sessions, Lunit will present the association between 3-IP classification and genomic profile in pan-carcinoma, as well as prediction of molecular subtypes in endometrial cancer.
For the 3-IP classification study, the team analyzed TCGA data, known to be the best established dataset among cancer genome public databases. Upon analyzing more than 7,000 data of 20 carcinomas with AI, the research team found that plausible immune intrinsic resistance pathways are highly enriched in ‘immune-excluded’ phenotype, suggesting that the spatial analysis of TIL immune cells can be important in understanding patient response to immunotherapy.
“The studies prove the association between the spatial distribution of immune cells and genomic profile,” said Chanyoung Ok, Chief Medical Officer of Lunit, who led the studies. Through the 3-IP classification using Lunit AI, it predicts the carcinoma that requires more sophisticated and accurate treatment and suggests the possibility of providing customized treatment to patients.”
Along with the endometrial cancer subtype study that once again supports the importance of TIL analysis in providing treatment insight, Lunit will also share a study suggesting that chest CT image analysis can be useful in estimating high-grade histologic patterns of lung adenocarcinoma, predicting clinical outcomes of patients with advanced lung cancer.
“The presence of high-grade histologic patterns in patients with lung adenocarcinoma is known to have a poor prognosis,” said Kyunghyun Paeng, Chief Product Officer of Lunit. “However, since it is difficult to determine the histologic pattern of the entire tumor with a small biopsy sample, there is a growing need for non-invasive biomarkers. This study suggests the possibility of Lunit AI to use CT image to recognize the pattern of a larger tumor area.”
Lunit's research was conducted in collaboration with Seoul National University Bundang Hospital and Samsung Medical Center. A world-renowned medical oncologist, Dr. Tony Mok, also an adviser at Lunit, participated in the study.
“Studies with top experts in the field are of great significance for the analysis of reliable data to derive meaningful results,” said Brandon Suh, CEO of Lunit. “We will continuously conduct further research and develop our platform so that Lunit AI can bring a new paradigm in the field of cancer treatment.”
Lunit Abstract Information at AACR 2021
Virtual Meeting: E-Posters
April 10, 2021 8:30 AM - 11:59 PM
Title: Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes reveals distinct genomic profile of immune excluded phenotype in pan-carcinoma
Session PO.IM01.09 - Tumor-Induced Immune Suppression: Intrinsic and Extrinsic Factors
Title: Artificial intelligence-powered tissue analysis reveals distinct tumor-infiltrating lymphocyte profile as a potential biomarker of molecular subtypes in endometrial cancer
Session PO.CL01.04 - Molecular Classification of Tumors / Tumor Staging
Title: Deep learning based radiomic biomarker for predicting the presence of high-grade histologic patterns in lung adenocarcinoma
Session PO.CL01.01 - Clinical, Functional, and Molecular Imaging / Radiomics
Lunit wins Tumor Proliferation Assessment Challenge (TUPAC) 2016
Lunit to unveil data-driven imaging biomarker at RSNA 2016
Lunit to showcase AI-powered products at USCAP 2017
Lunit INSIGHT: The First-ever, Real-time Imaging AI Analytics on the Web
Uncertainty and Deep Learning
Lunit Returns to RSNA with Real-time Imaging Platform, Featuring Cloud-based A
Lunit Unveils “Lunit INSIGHT,” A New Real-time Imaging AI Platform on the Web at RSNA 2017
Lunit INSIGHT: Q&A with Brandon B. Suh, Chief Medical Officer at Lunit
ANNOUNCING: BRANDON SUH, OUR NEW CEO
Lunit preps Korean IPO led by NH Investment Bank
Media Advisory: Lunit at RSNA 2018
Lunit Opens “Lunit INSIGHT for Mammography” for Public Access
Lunit Brings its Newest AI Solution for Mammography to RSNA 2018
Lunit Partners with Fujifilm and Salud Digna to Provide Medical AI Solution in Mexico
Lunit announces new members in its advisory board: Dr. Eliot Siegel, Dr. Linda Moy, and Dr. Khan Siddiqui
Lunit to Introduce Medical AI Solutions at GTC 2019
Lunit to Present Abstracts on AI-powered Precision Pathology at 2019 AACR Annual Meeting
Lunit to Showcase AI Solution for Breast Cancer at SBI 2019
Lunit to Present Findings on the Predictive Power of AI Biomarker for Lung Cancer Immunotherapy at ASCO 2019
Lunit Receives Korea MFDS Approval for its AI Solution for Breast Cancer, Lunit INSIGHT MMG
Lunit Named to the 2019 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
Lunit at RSNA 2019
Lunit Announces its First CE Mark for AI-Powered Chest X-ray Analysis Software, Lunit INSIGHT CXR
Lunit AI software clinically installed in global sites—to be presented at RSNA 2019
Lunit Secures $26M in Series C Funding Round, Led by Asian Investors
Renowned Oncologist Dr. Tony Mok Joins Lunit Advisory Board
Lunit to Present Findings on the Predictive Power of AI-based Analysis of Immune Phenotype at ASCO 2020
Lunit Awarded as Technology Pioneer by World Economic Forum
Lunit at ECR 2020: Providing Virtual Exhibition and Online Presentations
Lunit Named to the 2020 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
Emergent Connect Partners with Lunit to Provide Cloud Based AI Solutions
AI has Added Value in Insurance Underwriting Process, Recent Pilot Project Between Lunit and Cathay Financial Innovation Lab Reveals
RSNA 2020--Lunit Collaborates with Global Giants in Presenting its AI Solution at Virtual Booths of GE Healthcare, FujiFilm, and Sectra
Lunit Expands Collaboration with GE Healthcare to Advance AI Adoption across Healthcare Industry
What do medical studies say about AI for COVID-19 management?
What do the medical journals say about AI-powered mammography?
Research Using Lunit Demo Website
Lunit Presents AI-powered Pathologic Classification of Immune Phenotype that Predicts Response to Immunotherapy at USCAP 2021
What do the medical journals say about AI-powered chest x-ray interpretation?
Join our webinar with Dr. Fredrik Strand
From retrospective to prospective trials of AI in breast cancer screening
Will AI Identify Breast Cancer Better Than Radiologists in Actual Clinical Screening?
Case of the Month | Where Is Breast Cancer?
AI-based Analysis of Cancer Tissue Predicts Response to Immunotherapy--Findings to Be Presented at ASCO 2021
Clinical Application of Lunit AI For Chest Radiography and Mammography to Be Presented at AOCR 2021
Lunit Secures $26M Investment from Guardant Health in a Strategic Funding Round
A Multi-reader Study Finds Unnecessary CT Exams Can Be Reduced by 30% When Analyzing Chest Radiographs with AI
Fujifilm Introduces its AI-powered Product for Chest X-ray in Japan, in Collaboration with Lunit
Lunit Collaborates with Intel to Provide AI Solutions to CPU-Based Customers in Need of Effective X-ray Diagnosis
Lunit AI Applied to Clinical Trial for Drug Development for the First Time--Findings Presented at ESMO 2021